Featured Research

from universities, journals, and other organizations

Blood-pressure-lowering Drugs Should Not Be Limited To People With High Blood Pressure

Date:
May 26, 2009
Source:
BMJ-British Medical Journal
Summary:
Blood-pressure-lowering drugs should be offered to anyone old enough to be at risk of a heart attack or stroke (or who is otherwise known to be at risk), regardless of their blood pressure, according to the largest analysis of blood pressure trials to date.

Blood pressure lowering drugs should be offered to anyone old enough to be at risk of a heart attack or stroke (or who is otherwise known to be at risk), regardless of their blood pressure, according to the largest analysis of blood pressure trials to date, published on the British Medical Journal website.

Cardiovascular disease is the leading cause of death throughout the world. For 65 year olds in England and Wales the risk of having a heart attack in the next 10 years is about 10% for men and 5% for women. The increase in blood pressure during a person's life, which affects nearly everyone, is one of the main reasons for strokes and heart attacks being so common.

Despite the widespread use of blood pressure lowering drugs and the results of many randomised trials, uncertainty remains about which drugs to use and whom to treat. For example, does the preventive effect of drugs differ in people with and without a history of heart disease? And should blood pressure lowering drugs be limited to people with high blood pressure?

To answer these questions, Professor Malcolm Law and colleagues from the Wolfson Institute of Preventive Medicine at Barts and The London School of Medicine analysed the findings of 147 blood pressure trials published between 1966 and 2007, involving 464,000 people.

The results show that using any one of the main classes of blood pressure lowering drugs at standard dose reduced fatal and non-fatal heart attacks by about a quarter and stroke by about a third. Heart failure was also reduced by about a quarter. The reductions in disease were similar in people with and without clinical cardiovascular disease and regardless of blood pressure before treatment.

All the classes of blood pressure lowering drugs had a similar effect for a given reduction in blood pressure that was accurately predicted from epidemiological studies of blood pressure and subsequent disease with two exceptions—an extra protective effect of beta-blockers given shortly after a heart attack and a small additional effect of calcium channel blockers in preventing stroke.

And combining the results with two previously published studies showed that three drugs together, each at low dose to minimise side effects, could increase the preventive effect, reducing heart attacks by about 45% and stroke by about 60%.

Professor Malcolm Law said "The results show that blood pressure lowering drugs should be offered to anyone at sufficient risk to benefit from treatment, whatever their reason for being at risk." However, the exact age range for being most at risk of heart attack and stroke could not be defined precisely from this study, which only looked at randomised trials in people aged 60󈞱.

In an accompanying editorial, Richard McManus from the University of Birmingham and Jonathan Mant from the University of Cambridge, say that these findings reinforce the view that treatment to lower blood pressure should be offered on the basis of risk, regardless of blood pressure. These data support the use of a polypill to lower the risk of cardiovascular disease in people at high risk without first checking their blood pressure, they add.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Blood-pressure-lowering Drugs Should Not Be Limited To People With High Blood Pressure." ScienceDaily. ScienceDaily, 26 May 2009. <www.sciencedaily.com/releases/2009/05/090519214950.htm>.
BMJ-British Medical Journal. (2009, May 26). Blood-pressure-lowering Drugs Should Not Be Limited To People With High Blood Pressure. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/05/090519214950.htm
BMJ-British Medical Journal. "Blood-pressure-lowering Drugs Should Not Be Limited To People With High Blood Pressure." ScienceDaily. www.sciencedaily.com/releases/2009/05/090519214950.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins